{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:45:18Z","timestamp":1781754318558,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.nmd.2006.12.001","type":"journal-article","created":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T15:25:41Z","timestamp":1176909941000},"page":"499-505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Issues in SMA clinical trial design"],"prefix":"10.1016","volume":"17","author":[{"given":"P.","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2006.12.001_bib1","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1212\/01.wnl.0000183282.10946.c7","article-title":"Challenges opportunities in clinical trials for spinal muscular atrophy","volume":"65","author":"Hirtz","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000223353.34006.54","article-title":"Neuroproctective agents for clinical trials in ALS: a systematic assessment","volume":"67","author":"Traynor","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib3","unstructured":"<http:\/\/www.fda.gov\/cder\/guidance\/2353fnl.pdfFOoIM. Edited by; 1999\/>."},{"key":"10.1016\/j.nmd.2006.12.001_bib4","unstructured":"ctep.cancer.gov\/forms\/CTCAEv3.pdf."},{"key":"10.1016\/j.nmd.2006.12.001_bib5","series-title":"Fundamentals of Clinical Trials","author":"Friedman","year":"1998"},{"key":"10.1016\/j.nmd.2006.12.001_bib6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis","volume":"330","author":"Bensimon","year":"1994","journal-title":"ALS\/Riluzole Study Group. N Engl J Med"},{"key":"10.1016\/j.nmd.2006.12.001_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2006.12.001_bib8","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1212\/WNL.47.6_Suppl_4.242S","article-title":"A confirmatory dose-ranging study of riluzole in ALS. ALS\/Riluzole Study Group-II","volume":"47","author":"Lacomblez","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis","volume":"61","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1212\/01.wnl.0000196641.05913.27","article-title":"Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial","volume":"66","author":"Kaufmann","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib11","unstructured":"Hall CT. Dying doctor\u2019s noble choice. Stricken S.F. neurologist enters own \u2018placebo\u2019 trial. San Francisco Chronicle 2005."},{"key":"10.1016\/j.nmd.2006.12.001_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.0006-341X.2002.00237.x","article-title":"On the use of nonparametric curves in phase I trials with low toxicity tolerance","volume":"58","author":"Cheung","year":"2002","journal-title":"Biometrics"},{"key":"10.1016\/j.nmd.2006.12.001_bib13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.nmd.2006.12.001_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.0006-341X.2002.00671.x","article-title":"A simple technique to evaluate model sensitivity in the continual reassessment method","volume":"58","author":"Cheung","year":"2002","journal-title":"Biometrics"},{"key":"10.1016\/j.nmd.2006.12.001_bib15","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1212\/01.wnl.0000201182.60750.66","article-title":"A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS","volume":"66","author":"Levy","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.12.001_bib16","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.0000185722.99167.56","article-title":"The utility of futility","volume":"36","author":"Levin","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.nmd.2006.12.001_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/sim.4780131704","article-title":"An optimal three-stage design for phase II clinical trials","volume":"13","author":"Ensign","year":"1994","journal-title":"Statistics in medicine"},{"key":"10.1016\/j.nmd.2006.12.001_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.nmd.2006.12.001_bib19","unstructured":"<http:\/\/www.myozyme.com\/PDF\/mz_pi.pdf\/>."},{"key":"10.1016\/j.nmd.2006.12.001_bib20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/14660820410021320","article-title":"Sequential designs for clinical trials in amyotrophic lateral sclerosis","volume":"5","author":"Groeneveld","year":"2004","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.12.001_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.nmd.2004.09.004","article-title":"Sleep disordered breathing in spinal muscular atrophy","volume":"14","author":"Mellies","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy","volume":"25","author":"Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.12.001_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mus.10050","article-title":"Motor unit number estimation in infants and children with spinal muscular atrophy","volume":"25","author":"Bromberg","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.12.001_bib26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ana.20473","article-title":"Natural history of denervation in SMA: relation to age, SMN2 copy number, and function","volume":"57","author":"Swoboda","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.12.001_bib27","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.nmd.2004.04.004","article-title":"Concerns about the design of clinical trials for spinal muscular atrophy","volume":"14","author":"Crawford","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib28","first-page":"1181","article-title":"Spinal muscular atrophy. A 4-year prospective, multicenter, longitudinal study (168 cases)","volume":"189","author":"Barois","year":"2005","journal-title":"Bull Acad Natl Med"},{"key":"10.1016\/j.nmd.2006.12.001_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2006.03.005","article-title":"The gross motor function measuretrade mark is a valid and sensitive outcome measure for spinal muscular atrophy","author":"Nelson","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneur.59.9.1445","article-title":"Outcome measures for pediatric spinal muscular atrophy","volume":"59","author":"Iannaccone","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2006.12.001_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.nmd.2005.11.010","article-title":"Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study","volume":"16","author":"Mercuri","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1090-3798(03)00060-6","article-title":"The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation","volume":"7","author":"Main","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2006.12.001_bib33","first-page":"485","article-title":"A motor function measurement scale for neuromuscular diseases \u2013 description and validation study","volume":"162","author":"Berard","year":"2006","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.nmd.2006.12.001_bib34","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nmd.2005.03.004","article-title":"A motor function measure for neuromuscular diseases. Construction and validation study","volume":"15","author":"Berard","year":"2005","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.12.001_bib35","unstructured":"<http:\/\/www.amsmart.org\/\/>."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606006286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606006286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:55:15Z","timestamp":1760774115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896606006286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S0960896606006286"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2006.12.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Issues in SMA clinical trial design","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2006.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}